Wechselwirkungen · Biktarvy
Biktarvy 30 mg/120 mg/15 mg film-coated tablets Biktarvy 50 mg/200 mg/25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 10–11
HOS-139300 · Präparat HOS-098314
10 Medicinal product by Effects on medicinal product Recommendation concerning therapeutic areas/possible levels. co-administration with Biktarvy mechanism of interaction Mean percent change in AUC, Cmax, Cmin Ferrous fumarate (324 mg single Bictegravir (simultaneous For non-pregnant patients: dose), Bictegravir administration, fasted): Biktarvy should be administered at AUC: ↓ 63% least 2 hours before oral (Chelation with polyvalent cations) Cmax: ↓ 71% medications or supplements containing iron, or taken together Bictegravir (simultaneous with food at any time. administration with food): AUC: ↔ For pregnant patients: Cmax: ↓ 25% Biktarvy should be administered at least 2 hours before or 6 hours after taking oral medications or supplements containing iron. Alternatively, Biktarvy and oral medications or supplements containing iron can be taken together with food at any time.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ferrous fumarate (HOS-139301) iron (HOS-085656)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-28T17:05:00Z · SHA-256 8ec4738243d92aa421e74b71a9bad453e15421c1f952d3be4e88479f189e0fe4 · Passage 0ae0f9e0f5eb08ae9fbe899305e69e94089deed4dc73831b9e3654eba7eb4e6a · Zeichen 16245–18240 im Abschnitt